Commissioner, Chief Counsel See Wiggle Room In FDA's Legal Powers
This article was originally published in The Rose Sheet
Putting FDA's aggressive enforcement plan into action will require more creativity on the part of agency lawyers, according to FDA's commissioner and chief counsel
You may also be interested in...
Steris is offering credits and rebates to users of its troubled System 1 liquid chemical sterilization system under a transition plan called for in an April 19 consent decree with FDA
A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program